Axsome CEO Herriot’s $13 M “buy‑sell” spree underscores bullish confidence amid FDA priority review and analyst upgrades.
CEO Tabuteau Herriot’s 2026 option‑exercise strategy shows Axsome’s leadership confident in its pain‑relief pipeline, boosting investor sentiment.
4 minutes to read